Bacillus anthracis remains a serious bioterrorism concern, and the currently licensed vaccine remains an incomplete solution for population protection from inhalation anthrax and has been associated with concerns regarding efficacy and safety. Thus, understanding how to generate long-lasting protective immunity with reduced immunizations or provide protection through postexposure immunotherapeutics are long-sought goals. Through evaluation of a large military cohort, we characterized the levels of antibodies against protective antigen and found that over half of anthrax vaccinees had low serum levels of in vitro toxin neutralization capacity. Using solid-phase epitope mapping and confirmatory assays, we identified several neutralizationassociated humoral epitopes and demonstrated that select antipeptide responses mediated protection in vitro. Finally, passively transferred antibodies specific for select epitopes provided protection in an in vivo lethal toxin mouse model. Identification of these antigenic regions has important implications for vaccine design and the development of directed immunotherapeutics.
priority, National Institute of Allergy and Infectious Diseases category A pathogen [1] . Even with aggressive antimicrobial treatment, the mortality rate of inhalation anthrax is 45%-90% [1] . This high mortality rate is likely related to both the overwhelming bacterial infection and the effects of the tripartite toxin.
Anthrax toxin is composed of 3 proteins: protective antigen, lethal factor, and edema factor. Cleavage of protective antigen by a furinlike endoprotease promotes oligomerization and binding of edema factor and/or lethal factor [1] [2] [3] . Lethal toxin is a zinc-dependent protease that causes macrophage lysis and death in animal models [1, 4] . Edema toxin is an adenylate cyclase that is also lethal to animals [5] and is able to increase cyclic adenosine monophosphate and impair macrophage phagocytosis [1, 6] . Protective antigen serves as a crucial component of both lethal toxin and edema toxin, and antibodies to protective antigen can provide protection from disease in animals [7, 8] . Indeed, passive transfer of antibodies against the major toxin proteins (protective antigen, lethal factor, and edema fac-tor) can provide protection against anthrax challenge [7] [8] [9] [10] [11] [12] .
The current US vaccine (anthrax vaccine absorbed [AVA]) is a cell-free filtrate of an attenuated bovine isolate [1, 13, 14] that had an onerous immunization schedule until recent evidence showed that dose reductions were not associated with statistically significant quantitative reductions in levels of antibodies to protective antigen [1, 14, 15] . Animal models have shown that AVA vaccination protects against challenge with nonencapsulated strains of B. anthracis [1] but not against fully virulent strains of B. anthracis [14, 16] . Human AVA vaccination results primarily in the production of antibodies to protective antigen [1, 15, 17, 18] , but the degree of protection offered by these antibodies, the fine specificity of the protective response of antibodies to protective antigen, and the humoral responses generated in real-world vaccination programs have not been fully elucidated.
This study addressed the protective aspects of human humoral immune responses to AVA vaccination. The neutralizing capacity of serum from AVA-vaccinated participants was dissected to determine the extent of active protection and to characterize the antibody specificities that represent effective immunity. Epitope target specificities of antibodies to protective antigen were identified and correlated with in vitro neutralization. In addition, select human antipeptide responses were characterized as protective in both in vitro and in vivo assays. By identifying the crucial elements of protective responses of antibodies to protective antigen, this work provides insights necessary for the generation of directed immunotherapeutics and refined vaccinations to enhance protective immunity to anthrax. The potential identification of a limited spectrum of antibody specificities for protection may enable more efficient and cost-effective production of passive immunization products, which are necessary for emergency protection of immunocompromised populations as well as postexposure treatment scenarios.
METHODS

Human subjects. Vaccinated individuals (
) with at n p 200 least 3 AVA immunizations participated in the study. Volunteers provided informed consent and information about vaccination, sex, age, and race. One hundred nonvaccinated individuals served as control subjects. Institutional review board approval was obtained from Oklahoma Medical Research Foundation, Oklahoma University Health Sciences Center, and Walter Reed Army Medical Center. Serum and plasma samples were collected and stored at Ϫ20ЊC.
Standard and peptide-specific enzyme-linked immunosorbent assays (ELISAs). Each well of 96-well plates was coated with 1 mg of recombinant protective antigen (BEI Resources) or у95% pure peptide (GenScript). The peptide sequences were 193 NSRKKRSTSAGPTVPDRDN 211, 259 FESDPYSDFEKVTGRID-KNVSPE 281 , and 637 EADESVVKEAHREVINSST 655 . A standard ELISA was used to add diluted serum, followed by an antihuman immunoglobulin G (IgG) and substrate, with appropriate washing between steps. The optical density (OD) was measured, and the end point titer was calculated by use of the following formula: mean OD plus 2 times the standard deviation (SD) for the control subjects. The concentration of antibodies to protective antigen was calculated using reference serum AVR801 (BEI Resources) containing antibodies to protective antigen serially diluted 2-fold at a concentration of 109.4 mg/mL [19] . Serum samples were tested at a dilution 1:100, and samples that could not be interpolated at this dilution were repeated at a dilution of 1:10 or 1:1000.
Lethal toxin neutralization. Inhibition of lethal toxin activity was performed as described elsewhere [20] , with a few modifications. RAW264.7 macrophages were plated into flatbottom tissue culture plates and incubated overnight. Serum was diluted at 1:100 and incubated with lethal toxin (50 ng of protective antigen and 50 ng of lethal factor). For neutralization with column-absorbed fractions, fractions were diluted at 1:5. Next, 100 mL of the serum-toxin mixture was added. Cells alone, protective antigen only, lethal factor only, or lethal toxin served as controls. After 2 h of incubation, 10 mL of WST-8 (cell counting kit 8; Dojindo) was added and incubated for 3 h.
The macrophage viability percentage was calculated by use of the following formula: OD of cells incubated with toxin divided by OD of cells incubated without toxin, times 100. A serum sample was considered to have low viability if the mean viability percentage from 3 independent experiments was below the neutralization cutoff value, as determined by use of the following formula: mean viability plus 2 times the SD for the unvaccinated control subjects (viability percentage, 12%).
Solid-phase peptide assay. Peptides that were 10 amino acids in length, overlapping by 8, and spanning the length of the protective antigen protein (PubMed sequence AAA22637) were covalently synthesized onto polyethylene rods [21] . Peptides were incubated with serum samples and conjugate by use of a modified ELISA protocol [21] , and the OD was determined. A region was defined as commonly antigenic if the OD for the antipeptide response was greater than the mean peptide OD of the control group plus 2 times the SD (mean ‫ע[‬ SD] cutoff value, ) and 150% of the vaccinated individuals 0.316 ‫ע‬ 0.063 tested positive.
Column absorption. Peptides from the furin cleavage, ligand-binding, and receptor-binding sites were synthesized as multiple antigenic peptides by the Oklahoma University Health Sciences Center Molecular Biology Core Facility and bound to cyanogen-preactivated Sepharose 4B [21] . To absorb peptidespecific antibodies, serum samples were recirculated 6 times over the beads, eluted with glycine after each passage, and concentrated to a 1-mL volume. Column-absorbed antibodies were tested for reactivity to recombinant protective antigen and the peptides of interest by means of ELISA and for in vitro toxin neutralization.
Toxin challenge. Peptide-specific antibodies were enriched by means of column absorption. The amount of IgG was quantified with Nanodrop (spectroscopic analysis at an absorption of 280 nm) and tested for reactivity with recombinant protective antigen and peptides. Next, 30 mg of antibody was intraperitoneally injected into 6-week-old female A/J mice. Control mice received saline or 30 mg of IgG enriched from a nonvaccinated control subject. The mice were challenged 3 h later with 3 times the median lethal dose (LD 50 ) of lethal toxin (300 mg of protective antigen plus 125 mg of lethal factor; experimentally determined) injected intraperitoneally, and mortality was recorded. Survival curves and survival percentages were generated by using Prism (version 4.0; GraphPad). All animal procedures were reviewed and approved by the Oklahoma Medical Research Foundation Institutional Animal Care and Use Committee.
Statistical analysis. Nonparametric correlations (Spearman correlation) were used to test the significance of the relationship between titer of antibodies to protective antigen and toxin neutralization, age, number of vaccinations, and time since vaccination. An unpaired Student t test compared the toxin neutralization activity levels in recently vaccinated individuals to that in individuals with 13 years after vaccination. The relationship between the toxin neutralization activity level and the presence of peptide-specific antibodies was determined by means of x 2 tests. The effect of preincubation with peptidespecific antibodies on in vitro toxin neutralization was evaluated with a paired Student t test. A Mann-Whitney U test was used to determine the impact of passive transfer on survival after toxin challenge.
RESULTS
High titers of antibodies to protective antigen following AVA vaccination.
Two hundred human subjects who received the currently licensed anthrax vaccine and consented to having serum samples collected participated in this study. The number of vaccinations received, the mean time since the last vaccine dose, and the demographic characteristics are presented in Table  1 . All individuals had received at least 3 vaccinations, as previously deemed necessary for protective immunity [22] .
Of the vaccinated individuals, 95% had detectable antibodies to protective antigen ( Figure 1a ) and were divided into groups on the basis of the antibody titer (р1:10, 1:100, 1:1000, and у1:10,000). The antibody level was also quantified in each titerdefined group by use of the reference standard AVR801 [19] : the mean ‫ע(‬ SD) microgram content in each titer group was mg/mL for titers of р1:10, mg/mL for titers 7.6 ‫ע‬ 0.7 21.1 ‫ע‬ 3.3 of 1:100, mg/mL for titers of 1:1000, and 52.9 ‫ע‬ 9.8 180.4 ‫ע‬ mg/mL for titers of 1:10,000. In our study, the level of 27.65 antibodies to protective antigen correlated with the number of vaccinations received but not with age ( and , P ! .001 P p .22 respectively) ( Figure 1b ). In addition, the participants with the highest titers of antibodies were those who had been most recently vaccinated (mean ‫ע[‬ SD] time since vaccination, years; ) ( Figure 1b ). These data are consistent 1.1 ‫ע‬ 0.8 P ! .001 with those in previous reports, which showed that titers of antibodies to protective antigen decrease over time [17, 23, 24] .
Over half of vaccinated individuals generate only low levels of antibodies capable of in vitro lethal toxin neutralization.
The ability of antibodies to protective antigen from AVA-vaccinated individuals to inhibit lethal toxin activity, as measured by in vitro toxin neutralization, is shown in Figure 2a . Participants were classified into 4 groups on the basis of their serum responses in this assay: high responders (macrophage viability percentage, 51%-100%), medium responders (macrophage viability percentage, 26%-50%), low responders (macrophage viability percentage, 12%-25%), and very low responders (macrophage viability percentage, !12%). For comparison, the mean macrophage viability percentage ‫ע(‬ SD) of a group of 100 nonvaccinated control individuals was . On the 8.06% ‫ע‬ 1.02% basis of these criteria, 54% of those who were vaccinated were very low responders and thus did not have increased neutral- izing capacity compared with individuals who were not vaccinated (Figure 2b ). Of the 200 participants, only 41 (20.5%) had serum samples with 150% in vitro neutralization by this assay. The participants who were vaccinated within the year preceding enrollment (52%) had significantly higher toxin neutralization activity levels than those of the participants who were not vaccinated within 3 years of enrollment (16%; P ! ) ( Figure 2c ). Most importantly, 15 (7.5%) participants .001 vaccinated within the past 2 years had titers of antibodies to protective antigen that were у1:1000 but were not able to neutralize lethal toxin in vitro.
Despite the lack of 100% concordance between titer of antibodies to protective antigen and neutralization in some participants, the most significant correlation with lethal toxin neutralization was titer of antibodies to protective antigen (P ! ; ) ( Figure 3 ), indicating that antibodies to pro-.001 r p 0.65 tective antigen tracked with protection in this assay. A direct correlation was found between the viability percentage of macrophages and the number of vaccinations received ( ; P ! .001 ) ( Figure 3 ). However, an inverse correlation was found r p 0.36 between the neutralization percentage and the time since vaccination ( ; ) (Figure 3) . Thus, the serum of P ! .001 r p Ϫ0.36 participants who were most recently vaccinated had higher neutralization activity levels. These data indicate that in most indi-viduals, repeated vaccination results in higher titers of protective antigen antibodies and that these antibodies correlate with in vitro neutralizing ability. No correlation was seen between the in vitro neutralizing activity level and other demographic features, such as age, race, or sex, in this cohort.
Select epitopes are associated with in vitro neutralization. Because the highest correlation with protection in the in vitro lethal toxin neutralization assay was titer of antibodies to protective antigen, we analyzed the fine-specificity response of antibodies to protective antigen with solid-phase peptide-binding assays. Antigenic regions were identified for the antibodies of those participants who had high or moderate levels of neutralizing antibodies and those who had antibodies to protective antigen but very low levels of lethal toxin neutralization ( Figure  4 ). On the basis of previous reports [1, [25] [26] [27] [28] [29] , we identified the location of each epitope on the protective antigen crystal structure, the domain locations, and proposed function of each epitope (Figure 4 ).
Because we were most interested in antibodies that are potentially neutralizing, we focused on epitopes identified in participants with high titers of neutralizing antibodies. The most prominent epitope identified in serum from participants with high lethal toxin neutralization activity levels was epitope 4 (amino acids 181-200), which was identified as the region con- taining the furin cleavage site [1, 28] . In fact, 83% of the individuals with high titers of neutralizing antibodies had responses directed against this antigenic region. An epitope within the ligand-binding region (identified as epitope 6; amino acids 261-275) ( Figure 4 ) was of particular interest because mutagenesis in this region was previously shown to be critical for ligand-binding and lethal toxin activity [28] . A third potentially important epitope was identified in 66% of the individuals with high neutralization and is within the receptor-binding domain of protective antigen (epitope 12) ( Figure 4) .
To confirm the antibodies directed against these epitopes of interest with a second method, we synthesized these epitopes as soluble peptides and used them in peptide-specific ELISAs. We identified 28 different study participants (14%) whose serum contained antibodies directed to the furin cleavage site epitope, 30 participants (15%) who had antibodies directed to the ligand-binding domain epitope, and 29 participants (14.5%) who had antibodies directed to the receptor-binding domain epitope. Peptide antibodies directed against the furin cleavage and receptor-binding sites were more common among participants whose serum had high neutralizing activity levels ( ), but there was no relationship between neutralizing P p .04 activity level and the anti-ligand-binding domain antibodies.
Select antipeptide antibodies provide in vitro lethal toxin neutralization. Once these unique antigenic regions had been identified and confirmed, we enriched human serum for peptide-specific antibodies by means of column absorption. The absorption resulted in a 78.8% depletion of the furin-cleavage site-specific antibodies, a 90.5% depletion of the ligand-binding site antibodies, and a 91% depletion of the receptor-binding site antibodies in the unretained fractions. Each of these enriched samples retained the ability to bind to whole recombinant protective antigen.
These column-absorbed samples were then used in the in vitro lethal toxin neutralization assay to test the ability of these peptide-specific antibodies to mediate protection. Whole serum from vaccinated individuals or affinity purified antibodies directed against the 3 specific epitopes significantly increased macrophage cell survival in the lethal toxin neutralization assay ( ) ( Figure 5a ). In contrast, depletion of these peptide-P p .03 specific antibodies resulted in loss of toxin neutralization (mean viability percentage, 12%). IgG affinity purified from nonvaccinated control subjects showed no ability to neutralize lethal toxin activity, indicating that this protection was not due to inhibition via nonspecific interactions.
Select antipeptide antibodies provide protection against lethal toxin challenge in vivo.
Antibodies specific for each of the 3 epitopes of interest were column enriched and then passively transferred to A/J mice to measure in vivo protection. After passive transfer of antipeptide enriched samples or sham antibody controls, mice were challenged with of lethal 3 ϫ LD 50 toxin and mortality was recorded (Figure 5b ). Sixty percent of mice receiving receptor-binding site epitope antibodies survived the lethal toxin challenge ( ). In contrast, only 30% of P p .002 mice receiving ligand-binding site antibodies and 10% of mice receiving furin cleavage site-specific antibodies survived lethal toxin challenge ( and , respectively). All control P p .05 P p .36 mice, which received no antibodies or nonspecific IgG, suc- cumbed to death by day 2 after challenge. These data indicate that select protective antigen peptide-specific antibodies provide protection from lethal toxin challenge in vivo.
DISCUSSION
The US anthrax vaccine is predicated on evidence that antibodies directed against protective antigen provide protection against challenge. Studies with animal models, including rabbits and guinea pigs, have shown that although antibodies to protective antigen and in vitro toxin neutralization titers predict survival in an aerosol spore challenge model, this prediction is imperfect [16, 30] . Since then, several groups have performed limited studies to characterize the immune response among individuals who receive the AVA vaccine. These studies have shown that, as with animals, humans vaccinated with AVA produce high titers of antibodies to protective antigen and that antibody titer and in vitro neutralization are correlated [23, 24, 31, 32] . However, in each of these studies, there were individuals who generated high titers of antibodies to protective antigen but were not able to neutralize the toxin. Therefore, it is probable that antibody qualities such as epitope specificity are important factors for effective toxin neutralization. Results from this study provide a biological explanation for the observations of discordance between high concentrations of antibodies and low neutralizing capacities.
In our cohort of AVA-vaccinated participants, 95% had measurable antibodies to protective antigen and lower concentra-tions were associated with longer time since the last vaccination and lower total number of doses. Thus, the participants with the highest titers of antibodies received more vaccinations (4-6) and were among those most recently vaccinated (mean ‫ע[‬ SD] time since vaccination, years). These data are 1.1 ‫ע‬ 0.8 consistent with those in previous reports, which showed that titers of antibodies to protective antigen decrease over time [17, 23, 24] .
Toxin neutralization is a critical component of protection [17, 23, 24, 31] , and the level of neutralizing antibodies is the best surrogate marker for protective immunity that has been found to date [30] . Over half of the vaccinated individuals (54%) had little in vitro neutralizing activity above that seen in unvaccinated control subjects, and only 21% had у50% neutralization levels at a 1:100 dilution. Although it is unclear whether these individuals would be at risk following exposure, a recent study used serum from AVA-vaccinated individuals to determine the concentration of protective antigen-specific antibodies necessary for protection. Using a Sterne strain challenge in mice, the researchers found that a toxin neutralization titer of у280 mg/mL (corresponding to a neutralization level of 50% at a 1:112 dilution) provided protection in 79% of mice [33] . These data highlight the need for improved understanding of the variables that determine the quality of vaccine response and the potential for different vaccine designs and dosing strategies, as well as the desirable properties of specific antibodies used for passive immunization after spore exposure. Because the highest correlation with in vitro lethal toxin neutralization was titer of antibodies to protective antigen, we analyzed the fine specificity of the response of antibodies to protective antigen and identified neutralization-associated humoral epitopes. Although there are reports that detail the levels of antigen-specific antibodies following AVA vaccination [34] [35] [36] [37] , the humoral epitope-binding patterns and protective capacity of select specificities have not been well characterized.
We identified 13 unique antibody-binding domains after AVA vaccination within all 4 protective antigen domains [1, 28] . Three of the antigenic regions were in the 20-kDa region of protective antigen that is cleaved off by furin, and recent evidence indicates that antibodies to this domain can prolong survival of mice challenged with the toxin [38] . An epitope that was identified in serum of participants with high toxin neutralization activity levels was within the furin cleavage site. Several studies have demonstrated that antibodies or small molecule inhibitors that prevent or slow furin cleavage can provide protection in vivo [39] [40] [41] [42] . Indeed, Abboud et al [43] generated a neutralizing monoclonal antibody in mice that bound to a linear epitope within the furin cleavage site (QKSSN), which is contained within our epitope 4.
Two epitopes were identified in the ligand-binding domain, and mutations in this region have been shown to reduce lethal factor binding and inhibit toxin activity [26] . The 2 epitopes found in domain II contain amino acids that are necessary for toxin translocation [28] , as well as sequence homology to the antigenic region (SKNLAPI) bound by a murine monoclonal antibody that provides protection from Sterne strain challenge [39] . We also identified an antigenic region in the critical re- ceptor-binding domain. Mutations of amino acids within this region result in partial or complete loss of toxicity [29] , and murine monoclonal antibodies to this region neutralize toxin activity in vitro and in vivo [25, 44, 45] . The antigenic regions within the receptor-binding domain that we identified did not overlap with those found by other researchers [25, 44] . However, Kaur et al [45] immunized mice with an antigenic region, which they designated ID-II, that contained our epitope 12 (LLNIDKDIRK), and demonstrated both in vitro and in vivo protection.
A recent study by Gubbins et al [46] demonstrated that AVA-vaccinated individuals generate antibodies to the translocation domain (SFFD), but it is not clear if the antibodies in that study mediate protection. In addition, others have demonstrated that antibodies from vaccinated individuals directed against the receptor-binding and the ligand-binding regions can provide in vitro protection [47] . However, the ability of these antibodies to protect against in vivo challenge has not been tested.
We enriched for peptide-specific antibodies against the furin cleavage, ligand-binding, and receptor-binding regions and demonstrated that these antibodies are capable of in vitro neutralization. The neutralizing activity in the unretained samples is likely due to either low levels of antibodies directed against these 3 regions that were not removed by absorption or to antibodies specific for other peptides, because these antibodies account for only 3 of the antigenic regions identified in the high responders.
Surprisingly, we found that although the antibodies directed to the furin cleavage site mediated the best protection in vitro, the receptor-binding site antibodies resulted in the most robust protection in vivo, despite their apparently equivalent affinity. This may be due in part to rapid furin cleavage and binding of lethal factor to protective antigen before the epitope-specific antibody can bind its target. Preincubation of protective antigen with the antifurin cleavage site antibody probably decreases toxin activity levels, but this scenario is unlikely to occur naturally. The receptor-binding antibody, however, would be able to bind to the cellular receptors before the toxin was administered and could result in decreased toxin activity levels. This is consistent with a previous report showing that monoclonal antibodies to the receptor-binding region have neutralizing activity [25] . Thus, we have demonstrated that epitope-specific antibodies derived from AVA-vaccinated individuals can provide protection against lethal toxin challenge.
To our knowledge, this is the first study to perform a systematic characterization of the humoral fine-specificity response following human AVA vaccination. We have demonstrated that select peptide-specific antibodies enriched from the serum of vaccinated individuals can provide in vivo protection against lethal toxin challenge. The new anthrax vaccination schedule, based on quantitative levels of antibodies to protective antigen after doses, may need to be evaluated in the context of antibody specificities that are functionally effective in lethal toxin neutralization and critical to survival of challenge. In addition, the data presented suggest that it may be feasible to create a limited number of monoclonal mixtures that can provide highly effective passive immunity in a postexposure scenario.
